VAV1 gene alterations, including translocations and missense/deletion mutations, account for 18% of adult T-cell leukemia/lymphoma (ATLL), 11% of anaplastic large cell lymphoma (ALCL), 7% to 11% of peripheral T-cell lymphomas not otherwise specified (PTCL-NOS), and 5% in angioimmunoblastic T-cell lymphoma (AITL) (reviewed in [95]). Here, VAV1 is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.